•• REMARKS/ARGUMENTS ••

By the Present Preliminary Amendment corrects matters of grammar, sentence structure, syntax, sentence structure form in the specification and claims without changing the scope of the disclosure or adding any new matter thereto.

Entry of the present Preliminary Amendment prior to the examination of the present application is respectfully requested.

Respectfully submitted,



Michael S. Gzybowski
Reg. No. 32,816

BUTZEL LONG
350 South Main Street
Suite 300
Ann Arbor, Michigan 48104
(734) 995-3110

132483.1

Asiaticoside-liposome and the use thereof

Technical field

This invention belongs to the chemical ~~field, which~~ field and is related to the fields of pharmaceutical preparations and ~~cosmetic, especially~~ cosmetics. More specifically, the present invention is directed to ~~asiaticoside-liposome~~ asiaticoside-liposomes and ~~its~~ their use ~~for~~ in the ~~preparing~~ preparation of pharmaceutical ~~preparations~~ compositions and ~~cosmetic.~~ cosmetics.

Background technology

Centella asiatica(L.)Urban belongs to ~~Umbelliferae.~~ the Umbellifera family. Its herb can be used as an officinal, which has the effects of defervescence, diuretic, ~~detoxicating and anti-swelling~~ detoxicating, anti-swelling, etc. As a folk medicine in China, the extract of *Centella asiatica* is used as a remedy for jaundice with damp-heat pathogen, ~~wound and dermal ulcer~~ wounds, dermal ulcers, etc. ~~The existing~~ Existing data indicates that the component of triterpene saponins extracted from *Centella asiatica* can distinctly facilitate the wound healing process, stimulate the growth of ~~the~~ granulation, promote ~~the~~ keratinization of the epidermis, and redound to allow ~~the~~ generation of new connective ~~tissue, which~~ tissue. In addition, the component of triterpene saponins extracted from *Centella asiatica* can also be used as a remedy for ~~burn, the~~ burns, lower limb ulcers, wounds, adhesion of tendons, ~~limbs' ulcer, wound and adhesion of tendon~~ etc. Moreover, asiaticoside shows significant activity for scar-hyperplasia and keloid, and it can prevent skin from erythema induced by ultraviolet irradiation. Therefore ~~it becomes a research hotspot that~~ much interest exists for developing asiaticoside ~~would be developed~~ into functional ~~cosmetic to~~ cosmetics that can prevent and cure cutaneous ~~disease.~~ diseases.

Asiaticoside is a triterpene saponin. ~~While practicing use,~~ Attempts at practical use find that asiaticoside ~~is found that it~~ can hardly permeate skin because of its big molecular weight (approximate 936), bad liposolubility and ~~water-solubility; asiaticoside~~ water-solubility. In addition, asiaticoside is instable in air ~~or~~ and solutions and can easy to be oxidized ~~oxidated~~ and degraded because of the character of its ~~structure, which~~ structure. These factors influence the ~~preparing for~~ ability to prepare stable pharmaceutical preparations and ~~cosmetic prescription;~~ cosmetics. Moreover, bad liposolubility and water-solubility result in difficulties with the preparation process ~~that~~ because asiaticoside can not be mixed with other components of pharmaceutical ~~preparations~~ and ~~cosmetic.~~ cosmetic compositions and formulations. These disadvantageous factors restrict the further development and the application of asiaticoside in the field of pharmaceutical ~~preparations~~ compositions and formulations that are intended to be administered per cutem and ~~cosmetic.~~ cosmetic compositions and formulations. Therefore, a need exists ~~it is very important~~ to find a ~~kind of~~ suitable drug-carrier which can enhance the chemical stability and skin penetrability of asiaticoside so as to be convenient for the preparation of its pharmaceutical preparations and cosmetic.

Disclosure of the Invention

One aspect of ~~this~~ the present invention is to provide ~~a asiaticoside-liposome~~ asiaticoside-liposomes for skin use, ~~in allusion to the shortcoming lies in asiaticoside's~~ to overcome the previous inability to use asiaticoside ~~using~~ in pharmaceutical preparations that are intended to be administered per cutem and ~~cosmetic.~~ cosmetics.

Another aspect of ~~this~~ the present invention is to provide for the use of ~~asiaticoside-liposome~~ asiaticoside-liposomes for preparing pharmaceutical ~~preparations~~ compositions and formulations and ~~cosmetic~~ cosmetics which contain asiaticoside.

~~**Invention content**~~

Best Mode for Carrying out the Invention

~~Asiaticoside liposome is~~ The asiaticoside-liposomes of the present invention are a kind of opalescent suspension. It is just necessary to uniformly mix ~~asiaticoside liposome~~ the asiaticoside-liposomes with the other components ~~of prescription uniformly~~ when preparing pharmaceutical ~~preparations~~ compositions and formulations and cosmetics. ~~cosmetic.~~ The ~~asiaticoside liposome~~ asiaticoside-liposomes for skin use ~~is a kind of~~ are hydrophilic opalescent suspensions in which the asiaticoside is enwrapped in the middle of liposome bilayer membranes. ~~This~~ The present invention can enhance not only asiaticoside's stability but also its skin penetrability and hydrophilicity, and it is more propitious to prepare pharmaceutical ~~preparations~~ compositions and formulations and ~~cosmetic~~ cosmetics of ~~asiaticoside.~~ asiaticoside according to the present invention.

The ~~asiaticoside liposome~~ asiaticoside-liposomes for skin use ~~disclosed by this~~ provided by the present invention is prepared by the following methods and steps:

1. Asiaticoside monomer is isolated from the total saponins of *Centella asiatica* according to conventional methods;

2. The ~~said~~ asiaticoside and lipid components used in the liposomes ~~prescription~~ compositions and formulations are fused by heating or ~~dissolved~~ disolution in organic solvents to make a lipid solution;

3. The ~~said~~ lipid solution is placed into rotary evaporator, then a lipid film is ~~afforded~~ produced at the bottom of the vessel by the rotary thin layer evaporation technique;

4. ~~Lipid~~ A lipid dispersing aqueous solution is ~~afforded~~ produced after the ~~said~~ lipid film ~~had~~ has been hydrated by adding an aqueous solution ~~under shaking,~~ while shaking the resulting mixture, or ~~afforded~~ by mixing the lipid solution ~~mentioned in~~ from step 2 with an aqueous solution directly under shaking;

5. ~~Asiaticoside-liposome~~ The asiaticoside-liposome is obtained after the ~~said~~ lipid dispersing aqueous solution has been treated by using the ~~technics~~ techniques of ~~sonication,~~ sonification, homogeneous emulsification, microjet and extruding filtration.

~~Asiaticoside~~ The asiaticoside content ~~is 0.1~10%~~ in the ~~asiaticoside-liposome~~ asiaticoside-liposomes developed for skin use ~~disclosed by this invention.~~ according to the present invention is 0.1~10%.

In the liposomes ~~prescription~~ compositions and formulation of ~~this~~ the present invention, ceramide is included in the liposomal bilayer structure as an active component.

In addition, at least one ~~kind~~ of the following components should be included in the liposomes: soybean lecithin, yolk lecithin, distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, poloxamer, dimyristoyl phosphatidylcholine, tween, span, nonionic surfactant Brij, bile salt, cholesterol.

In the ~~liposomes prescription~~ liposome compositions and formulation of ~~this~~ the present invention, asiaticoside and lipid components of the liposomes account for 0.1~10% and 0.1~40% respectively.

The ~~said~~ organic solvents used according to the present invention include dichlormethane, chloroform, ~~aether,~~ ether, and ethanol.

The ~~said~~ aqueous solutions used according to the present invention include distilled water, deionized water, purified water, and phosphate buffer.

A method for the preparation of ~~a~~ liposomal emulsions containing ceramide is mentioned in ~~CN 98110614.5. Whererin~~ CN 98110614.5 in which drugs carried by the ~~liposome is~~ liposomes are provided with stable chemical ~~property, which~~ properties so that they are difficult to oxidize ~~be oxidated,~~ and have the function of skin protection such as ~~damp-keeping,~~ moisturizing, preventing ~~drying and~~ drying, desquamating, etc. These drugs can be easily absorbed by the skin. Therefore, the liposomes are ~~perfect~~ suitable as cosmetic ~~additive~~ additives and ~~drug-carrier~~ drug-carriers for

external use. ~~The analogous~~ Analogous methods in which liposomes are applied to the preparation of pharmaceutical preparations and ~~cosmetic~~ cosmetics ~~were~~ are disclosed ~~by~~ in ZL 96116044.6, CN 96192625.2, and CN 93114073.0.

~~Asiaticoside-liposome~~ The asiaticoside-liposomes of ~~this~~ the present invention can be applied to the preparation of pharmaceutical ~~preparations~~ compositions and formulations and ~~cosmetic.~~ cosmetics. The asiaticoside-liposomes can ~~It could~~ be prepared ~~by~~ using conventional methods or the methods described in aforementioned patent documents. ~~To form asiaticoside-liposome is useful to enhance~~ Forming the asiaticoside-liposomes according to the present invention enhances the stability, skin penetrability and hydrophilicity of asiaticoside so that it is more convenient and ~~logical~~ suitable to prepare cosmetic or pharmaceutical ~~preparations~~ compositions and formulations containing the asiaticoside.

~~Asiaticoside-liposome~~ The asiaticoside-liposomes of ~~this~~ the present invention are ~~is primarily~~ provided with the ~~advantages as undermentioned:~~ following advantages:

1. ~~To enhance asiaticoside's~~ The asiaticoside has enhanced stability. Drugs are enwrapped in the middle of liposomal ~~bilayer,~~ bilayers which can prevent the drugs from being destructed by instable factors such as light, oxygen, acid, base and so ~~on, consequently, drugs'~~ on. As a consequence, the stability of the drugs is enhanced. ~~Liposomes~~ It has been determined that the liposomes can enhance ~~drug's~~ the stability of drugs in both ~~not only~~ in vitro ~~but~~ and in vivo applications and ~~also in vivo, it can~~ prolong ~~drug's~~ action time of drugs ~~in vivo.~~ in in vivo applications.

2. ~~To enhance asiaticoside's~~ The asiaticoside has enhanced skin penetrability. ~~Liposome~~ Liposomes are drug carriers that are composed of lipid ~~bilayer,~~ bilayers which ~~has~~ have more comparability and compatibility with biological tissue, and can enhance ~~drug's~~ skin ~~penetrability.~~ penetrability of drugs. ~~Liposome can~~ Liposomes not only enhance ~~drug's~~ skin ~~penetrability,~~ penetrability of drugs, but also ~~remain more~~ retain larger quantity of drugs between

epidermis and ~~dermis, however~~ dermis however, the dosage entering into the hematological system is decreased, so that general adverse effects can be efficiently avoided. ~~avoided efficiently.~~ Liposomes can enhance ~~drugs'~~ the skin penetrability of drugs by the mechanism of hydration, ~~fusion and penetration~~ fusion, penetration, etc. Furthermore, plentiful ceramides are contained in stratum corneum of human skin. According to similarity-compatibility theory, liposomes containing ceramides in lipid ~~bilayer~~ bilayers can further enhance ~~drugs'~~ skin penetrability and ~~absorbability.~~ absorbability or drugs. ~~Asiaticoside-liposome~~ The asiaticoside-liposomes of ~~this~~ the present invention contain ceramides in the lipid ~~bilayer, they can~~ bilayers which allows them to further enhance ~~asiaticoside's~~ the skin ~~penetrability.~~ penetrability of asiaticoside.

3. The asiaticoside-liposomes of the present invention can ~~To~~ be mixed discretionarily with other components used in ~~the prescription and~~ compositions and formulations which make it more simple and convenient to prepare pharmaceutical ~~preparations~~ compositions and formulations and ~~cosmetic~~ cosmetice containing asiaticoside. In ~~prescriptions~~ compositions and formulations of most ~~cosmetic,~~ cosmetics the ground substance is hydrophilic or ~~emulsive, thus~~ emulsive. Thus, components of ~~prescriptions~~ the compositions and formulations should be hydrophilic or lipophilic. It is difficult to prepare ~~cosmetic~~ cosmetics containing asiaticoside because ~~of asiaticoside's~~ asaiticoside has bad hydrophilicity and lipophilicify. ~~Liposome is~~ Liposomes are a kind of drug carrier with high hydrophilicity, by which asiaticoside is encapsulated and the ~~drug's~~ hydrophilicity of the drug is thereby enhanced. ~~enhanced obviously, the~~ The encapsulated drug can then be mixed discretionarily with other components of the ~~prescription.~~ compositions and formulations. It is more simple and convenient to prepare pharmaceutical ~~preparations~~ compositions and formulations and ~~cosmetic~~ cosmetics containing asiaticoside.

Detailed examples

Example 1:

30g asiaticoside, 20g soybean lecithin, 30g cholesterol, 40g poloxamer F_{68}, 10g ceramide, 200 ml chloroform, l00ml ethanol and 1000ml phosphate buffer (pH 7.4) ~~were prepared. Asiaticoside, soybean lecithin, cholesterol, poloxamer F_{68} and ceramide aforementioned~~ were placed into a 1000ml round bottom flask, and dissolved ~~by the mixed~~ in a solution of chloroform and ~~ethanol, treated with the ratary~~ ethanol. The resulting mixture was subject to a rotary thin layer evaporation technique in a thermostatic waterbath at a temperature of 25~40°C~~, and then~~ so that a lipid film was ~~afforded~~ formed at the bottom of the flask. Then, 800ml phosphate ~~buffer(pH 7.4)~~ buffer (pH 7.4) was added to the ~~flask, after~~ flask. After the lipid film was hydrated under shaking, phosphate ~~buffer(pH 7.4)~~ buffer (pH 7.4) was added to the mixed solution to produce a volume of ~~1000ml, then~~ 1000 ml. Thereafter asiaticoside-liposome was ~~afforded~~ produced after sonification ~~(output4,~~ (output 4, duty cycle 50%, time 20 mins).

Example 2:

50g asiaticoside, 50g yolk lecithin, 50g cholesterol, 20g ceramide and 1000ml phosphate buffer (pH 7.4) were ~~prepared. Asiaticoside, yolk lecithin, cholesterol, and ceramide aforementioned were~~ placed into a conical flask and fused by heating or dissolved in organic solvent ~~stated in this invention to make lipid solution, then~~ to produce a lipid solution that was placed in a thermostatic waterbath at a temperature of 80°C. 800ml phosphate buffer (pH 7.4) was placed in a waterbath till its temperature ~~is~~ was the same as the temperature of the lipid solution. Then an ~~solution's, then~~ aqueous solution and the lipid solution were mixed together while ~~under~~ shaking the mixture which was ~~and~~ then cooled. Phosphate ~~cooled; phosphate~~ buffer (pH 7.4) was added to the mixed solution to produce a volume of 1000 ml. ~~1000ml, after~~ After homogenizing ~~for~~ 6 times ~~with~~ using a high pressure homogenization technique (higher pressure: 60MPa, lower pressure: 10MPa), asiaticoside-liposome was ~~afforded.~~ produced.

Example 3:

20g asiaticoside, 20g dipalmitoyl phosphatidylcholine, 30g poly-dioxyvinylcetylether, 40g cholesterol, 40g ceramide, 200ml dichlormethane, 200ml ethanol and 1000ml phosphate buffer (pH 7.4) were ~~prepared. Asiaticoside, dipalmitoyl phosphatidylcholine, polydioxyvinylcetylether, cholesterol and ceramide aforementioned were~~ placed into a 1000ml round bottom ~~flask,~~ and dissolved in ~~the~~ a mixed solution of dichlormethane and ethanol by ~~heating, treated with the ratary~~ heating. The resulting mixture was subjected to a thin layer evaporation technique in a thermostatic waterbath at a temperature of 25~40°C, ~~and then~~ to produce a lipid film ~~was afforded~~ at the bottom of the flask. Then, 800ml phosphate buffer (pH 7.4) was added to the ~~flask, after~~ flask. After the lipid film was hydrated under shaking, phosphate buffer (pH 7.4) was added to the mixed solution to produce a volume of 1000 ml. ~~1000ml.~~ The mixed solution was filtrated extrudedly from poly-(carbonic acid fibrous tunic) and then asiaticoside-liposome was ~~afforded.~~ obtained.

Example 4:

Stability experiment

~~The three groups of~~ Samples of each of the asiaticoside-liposome products produced in Examples 1-3 and an ~~aforementioned and~~ asiaticoside aqueous solution were placed airtight containers ~~respectively~~ at a temperature of 40°C, and a relative humidity 75%. The content of asiaticoside in asiaticoside-liposome samples and the asiaticoside aqueous solution was determined by HPLC after 0, 1, 2, 3 ~~month.~~ months. The content of asiaticoside in asiaticoside-liposome samples and the asiaticoside aqueous solution was assumed to be 100% at 0 ~~month, the~~ month. The content of asiaticoside at other ~~time~~ times was obtained comparing with it at 0 month, then the percentage that the ~~content~~ amount of drug changed with time was obtained. The result indicated that after placed for three months at a temperature of 40°C, and a relative humidity 75%, the content of asiaticoside in asiaticoside-liposome samples changed a little, but the content of asiaticoside in the

asiaticoside aqueous solution had decreased. ~~It proved~~ This proves that asiaticoside encapsulated by liposomes could enhance ~~drug's stability obviously.~~ drug stability.

Table 1 was the comparison of asiatoside's stability in liposomes and aqueous solution.

Table 1.

	The variety percentage of asiacoside's content (%)			
Time (month)	0	1	2	3
Liposomes	100.00	87.56	75.41	68.02
Aqueous solution	100.00	99.52	98,69	98.12

n=3